KORU Medical Systems, Inc. (KRMD) stock intrinsic value fair value estimate & owner earnings analysis

KORU Medical makes the FREEDOM infusion system: a small, battery-free syringe pump with matching needle sets and tubing that patients use at home, or in an infusion clinic, to give themselves subcutaneous immune globulin (SCIg) for conditions such as primary immunodeficiency and CIDP. The needle sets and tubing are used on every infusion. 2025 revenue was $41.1 million (up 22%): U.S. core $28.0 million (up 11%), international core $10.9 million (up 80%) and pharma services $2.3 million. Nine distributors account for about 77% of revenue; the three largest took 56% of product revenue in 2025 (64% in 2024), and the largest U.S. distributor is about 29% of the total. An earlier version of this analysis described a single customer at 56%; the filing describes three distributors, and the share has been falling. What the business has earned for its owners. After counting stock compensation as a real cost, removing working-capital swings, and deducting the capital spending needed to stay in business (including patent costs), owner earnings per share were slightly positive in 2017 to 2019 on a much smaller business ($0.02, $0.02 and $0.01) and have been negative in every year since: -$0.04 in 2020, -$0.14 in 2021, -$0.28 in 2022, -$0.21 in 2023, -$0.13 in 2024 and -$0.06 in 2025 (about -$2.6 million). Stock compensation alone was $2.7 million in 2025, 6.6% of sales. Reported operating cash flow flattered 2024: it was -$0.3 million, but included a $2.0 million inflow from working capital that we strip out, so owner earnings were -$6.1 million. We start from 2025, the first full year after the 2024 chief technology officer severance and the heavy 2021 to 2023 spending years, and we do not average in those earlier years because they describe a larger cash burn than the business now has. Where it stands now. In the first half of 2026 revenue was $23.8 million (up 20%), gross margin 63.3% (65.1% in the second quarter), and operating expenses rose 8.8%. The second quarter was profitable at the operating level ($0.63 million, net income $0.25 million), but the first quarter lost money and the six months together were still an operating loss of $0.24 million. One profitable quarter is not a level, so we do not move the starting point on it. We do credit the revenue already reached: the first-half pace is about $47.6 million a year, $6.5 million above 2025. We assume 30 cents of each extra revenue dollar reaches owner earnings; the company kept 46 cents in 2025 and 33 cents in the first half of 2026, so 30 is below both. That puts the current run-rate at roughly -$0.6 million a year, essentially break-even. In the second quarter a $0.37 million non-operating charge cut operating profit to net income; the available filing data does not say what it was, and we have not tried to explain it. Base case: $1.31 per share. Revenue grows 6% in 2027, tapering to 1.5% by 2036 (about $68.7 million), at the 30% flow-through, so owner earnings rise from about $0.2 million in 2027 to about $5.7 million in 2036 before tax, then stay flat. Growth reconciliation: owner earnings improved by $3.5 million in 2025 on revenue growth of 22%; the base case assumes revenue growth of 6% and an improvement of about $0.8 million in its first year, below the trailing figures. The growth credited is continued purchasing of needle sets and tubing by the existing patient base, at under half the 13% annual revenue growth of 2018 to 2025; revenue fell in only one of those years (2021, down 2.8%), gross margin has held between 62% and 65% since 2024, and the product is the market-leading U.S. system for these drugs. Left out: pre-filled-syringe adoption of the newer FreedomEdge pump, new drug partnerships beyond what is already cleared (Rystiggo, Empaveli), faster international growth and any margin gains beyond the 30% flow-through, because none has yet shown up in profit. Federal tax losses of $22.5 million (no expiry) largely shelter earnings for years, but they can only offset 80% of taxable income, and we assume a 25% tax rate once they run out. After the final year, earnings are held flat, with neither growth nor decline, because the installed patient base keeps needing supplies and the filing names no technology that has yet displaced the system. Worth: the business is worth about $60.6 million after tax; the company has no borrowings and a $0.22 million finance lease, and cash is $8.3 million, of which we hold back $4.0 million as working cash, leaving about $4.1 million of excess net cash ($0.08 a share). Total about $64.7 million over 49.5 million diluted shares. If only 25 cents of each extra dollar reached owner earnings the value would be $1.08; at 35 cents, $1.53; with growth cut in half, $0.56; with no growth the roughly -$0.6 million annual level would leave the shares worth about nothing. Bear case: $0.06 per share. All of its drivers are named in the filings. (1) Every current product is sold under a pre-2021 European certificate that is valid only until December 2028 unless the company completes EU Medical Device Regulation compliance; international core was 26.5% of 2025 revenue, and the filing says failure would stop EU sales. The filing does not split international sales between EU and other countries; the bear case assumes compliance slips so that roughly $6 million of revenue ($3.6 million of gross profit) is lost in 2029 and some in 2030. (2) Gross margin fell 1.1 points in 2025 on materials costs, tariff charges and international mix; the bear case takes 3 points off, about $1.4 million a year. (3) Revenue is flat at $47.6 million in 2027 and 2028 while compliance and development spending adds about $0.5 million in 2027 and $1.5 million in 2028. The company's own record is the evidence for this: between 2019 and 2022 revenue rose 20% while owner earnings fell from +$0.4 million to -$12.5 million because spending outran sales; this was a company-specific stumble rather than an industry downturn, because the therapy is chronic maintenance treatment and there is no industry downturn to borrow. Owner earnings then run about -$2.5 million, -$3.5 million, -$5.5 million, -$3.0 million and -$1.0 million for 2027 to 2031 before management restructures to a small profit of about $0.5 million a year. That burn of about $15.5 million far exceeds the $4.1 million of excess cash and would consume most of the $8.3 million of total cash, so we assume a $7 million raise at $0.35 a share (20 million new shares). Worth: the business is worth about -$7.0 million (burn exceeds the value of what is left), net excess cash $4.1 million, difference -$2.9 million before the raise; with the raise, about $4.1 million over 69.5 million shares. There is no debt to refinance, so shareholders are not wiped out by lenders, but they are left with almost nothing. Bull case: $3.57 per share. The company's own levers execute: revenue grows 12% in 2027 and tapers to 3% (domestic core grew 11% and international 80% in 2025), reaching $97.8 million by 2036, with 35 cents of each extra dollar reaching owner earnings (between the 33 and 46 cents achieved). Owner earnings reach about $16.9 million before tax in 2036. Worth: the business is about $172.8 million after tax, plus $4.1 million of excess net cash, no borrowings; about $176.9 million over 49.5 million shares. Margin-of-safety price: $0.30. How sure are we of the earnings level? Not very: owner earnings have been negative every year since 2020, the current run-rate is about break-even, and the one profitable quarter followed a loss quarter. The worst plausible outcome is the European certificate deadline in December 2028 landing on top of tariff pressure and a distributor that buys less (three distributors are 56% of product revenue), and all consumables subassemblies come from single suppliers; with no debt and $8.3 million of cash the company survives that, but the bear case shows it would need to sell new shares at a low price. If we are wrong about the two things most likely to be wrong, growth and flow-through, the shares are worth roughly $0.56 (half the growth) or $1.08 (25-cent flow-through) today; with half the growth they would be worth about $0.7 in five years. The price assumes a holding period of about five years. The company pays no dividend and currently produces no real owner earnings, so the only support during that period is the total net cash of about $0.16 a share. From $0.30 the half-growth outcome implies about 2.4 times the price in five years (about 19% a year), the cash alone covers more than half the price, and the bear case implies a loss of most of it. A higher price would rely on growth that has not yet turned into profit. Changes since the August 2026 analysis: the earlier figures ($0.44 bear, $2.15 base, $4.98 bull, margin-of-safety price $0.25) are not directly comparable, because they assumed profit margins would widen to 12% in the base case and 18% in the bull case; this update credits only the extra profit on revenue that is already booked, and it also reflects taxes once the loss carryforwards are used, a diluted share count of 49.5 million (from the June 2026 quarter) and the correction to the distributor concentration. The business news is mixed: first-half revenue up 20% and a profitable second quarter, the three largest distributors down from 64% to 56% of product revenue, but operating costs growing 8.8% and a European certification deadline about two years away.